AAI 202

Drug Profile

AAI 202

Alternative Names: AAI202; Anti-bacterial therapeutics - Allecra Therapeutics; Multi drug-resistant bacterial infections - Allecra therapeutics

Latest Information Update: 16 Jun 2016

Price : $50

At a glance

  • Originator Allecra Therapeutics
  • Class Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 15 Jun 2016 AAI 202 receives Qualified Infectious Disease Product status for Gram-negative infections in France
  • 15 Jun 2016 AAI202 receives eligibility for Fast track status from the US FDA for drug-resistant Gram-negative bacterial infections
  • 15 Jun 2016 Allecra Therapeutics plans a phase II trial for Allecra Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top